XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second‑line setting involving the sequential administration of XELOX and XELIRI

Suzuki,Koichi; Takaharu,Kato; Muto,Yuta; Ichida,Kosuke; Fukui,Taro; Takayama,Yuji; Tsujinaka,Shingo; Sasaki,Junichi; Horie,Hisanaga; Kawamura,Yutaka  J.; Konishi,Fumio; Rikiyama,Toshiki

doi:10.3892/mco.2014.306

September-October 2014 Volume 2 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-October 2014 Volume 2 Issue 5

Full Size Image

Article

XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second‑line setting involving the sequential administration of XELOX and XELIRI

Authors:
- Koichi Suzuki
- Kato Takaharu
- Yuta Muto
- Kosuke Ichida
- Taro Fukui
- Yuji Takayama
- Shingo Tsujinaka
- Junichi Sasaki
- Hisanaga Horie
- Yutaka J. Kawamura
- Fumio Konishi
- Toshiki Rikiyama
View Affiliations / Copyright

Affiliations: Department of Surgery, Saitama Medical Center, Jichi Medical University, Saitama 330‑8503, Japan, Nerima‑Hikarigaoka Hospital, Tokyo 179‑0072, Japan
Pages: 827-832
|
Published online on: June 6, 2014

https://doi.org/10.3892/mco.2014.306
Expand metrics +

Abstract

The aim of the present study was to present a retrospective review of 42 metastatic colorectal cancer (mCRC) patients treated using the XELIRI regimen as second‑line chemotherapy during the period between 2010 and 2012. Patients were treated with capecitabine, 1,600 (≥65 years) or 2,000 mg/m2 (<65 years), on days 1‑15, 200 mg/m2 irinotecan (CPT‑11) on day 1, with or without 7.5 mg/kg bevacizumab on day 1 and every 21 days. A total of 21 patients underwent XELIRI and 21 underwent XELIRI plus bevacizumab treatment. Fifteen patients received continuous administration of bevacizumab in the first‑ and second‑line settings [bevacizumab beyond progression (BBP)+], whereas 27 patients did not receive the treatment (BBP‑). Forty patients (95.2%), including all the patients in the BBP+ group, received sequentially administered XELOX and XELIRI regimens from the first‑ to the second‑line setting. The disease control rate (DCR), progression‑free survival (PFS), overall survival (OS) and adverse events were compared between the BBP‑ and BBP+ groups. The median relative dose intensity was similar (93.9% for capecitabine and 96.3% for CPT‑11 in the BBP‑ group vs. 94.8% for capecitabine and 91.5% for CPT‑11 in the BBP+ group). The DCR was 25.9% in the BBP‑ and 66.6% in the BBP+ groups (P=0.020). The median PFS was 3.5 months in the BBP‑ and 7.2 months in the BBP+ groups (P=0.028). The BBP+ group exhibited a higher median OS time compared to the BBP‑ group (12.5 months in the BBP‑ group vs. not reached in the BBP+ group; P=0.0267). The most common grade 3/4 adverse event (n≥20) was hypertension observed in the BBP+ group [three patients (20%)]: these three patients were well‑controlled with a single antihypertensive drug. Treatment with sequentially administered XELOX and XELIRI regimens did not aggravate adverse events in the 40 patients. The results showed that the XELIRI regimen, involving continuous treatment with bevacizumab, was well‑tolerated and effective as a second‑line chemotherapy and sequentially administering XELOX and XELIRI was feasible and manageable for patients with mCRC.

View Figures

View References

1	Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
2	Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 26:3523–3529. 2008. View Article : Google Scholar : PubMed/NCBI
3	Bennouna J, Sastre J, Arnold D, et al; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
4	Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 25:4779–4786. 2007. View Article : Google Scholar
5	Ducreux M, Adenis A, Pignon JP, et al: Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer. 49:1236–1245. 2013.
6	Ando Y, Saka H, Ando M, et al: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:6921–6926. 2000.PubMed/NCBI
7	Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 22:1382–1388. 2004. View Article : Google Scholar : PubMed/NCBI
8	Minami H, Sai K, Saeki M, et al: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A16 and 28. Pharmacogenet Genomics. 17:497–504. 2007. View Article : Google Scholar : PubMed/NCBI
9	O’Dwyer PJ and Catalano RB: Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 24:4534–4538. 2006.PubMed/NCBI
10	Schmiegel W, Reinacher-Schick A, Arnold D, et al: Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol. 24:1580–1587. 2013. View Article : Google Scholar
11	Yamaguchi T, Hamamoto Y and TN: A Phase I/II study of tri-weekly XELIRI plus bevacizumab for Japanese patients with mCRC as second-line chemotherapy (BIX study). Ann Oncol. 23:abstr P-0245. 2012.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second‑line setting involving the sequential administration of XELOX and XELIRI

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles